Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China
BackgroundThe data about the clinical features and outcomes of Chinese patients with follicular lymphoma (FL) are limited. Here, we conducted a retrospective study to explore the initial treatment strategies and clinical outcomes of Chinese patients with FL in the real world.MethodThis study include...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.863021/full |
| _version_ | 1811261471080841216 |
|---|---|
| author | Fenghua Gao Tingting Zhang Xia Liu Zhenjie Qu Xianming Liu Lanfang Li Lihua Qiu Zhengzi Qian Shiyong Zhou Wenchen Gong Bin Meng Xiubao Ren Xianhuo Wang Huilai Zhang |
| author_facet | Fenghua Gao Tingting Zhang Xia Liu Zhenjie Qu Xianming Liu Lanfang Li Lihua Qiu Zhengzi Qian Shiyong Zhou Wenchen Gong Bin Meng Xiubao Ren Xianhuo Wang Huilai Zhang |
| author_sort | Fenghua Gao |
| collection | DOAJ |
| description | BackgroundThe data about the clinical features and outcomes of Chinese patients with follicular lymphoma (FL) are limited. Here, we conducted a retrospective study to explore the initial treatment strategies and clinical outcomes of Chinese patients with FL in the real world.MethodThis study included FL patients who were newly diagnosed in Tianjin Medical University Cancer Institute and Hospital from March 2002 to August 2020.ResultsA total of 926 FL patients were enrolled. The median age was 54 years old, and the majority of the Chinese FL patients had advanced-stage disease and Eastern Cooperative Oncology Group(ECOG) <1 but less frequently infiltrated bone marrow. After a median of 38-month follow-up, the 5-year progressive-free survival (PFS) and overall survival (OS) of grade1–3a were 57.8% and 88.7%, respectively, which both are similar to those reported in previous Chinese and Western studies. The co-existence at diagnosis of FL and diffuse large B-cell lymphoma (DLBCL) components (FL/DLBCL) was associated with poor outcomes. The FL grades and proportion of DLBCL component in FL/DLBCL did not have an impact on PFS and OS. The most common regimen with great efficacy and risk–benefit was RCHOP-like followed by R maintenance regimen. The 5-year cumulative hazard of histological transformation (HT) was 4.7% (95% CI, 3.5–5.9); median time to transformation was 23.5 months (range, 2–146 months) after diagnosis. Three-year survival following transformation was 55% (95% CI, 40–70). Patients with stage III–IV, elevated β2 microglobulin (β2-MG), and B symptoms seemed to be more prone to progress within 24 months of frontline therapy (POD24). The FLIPI-2 showed the highest specificity to predict POD24, reflecting the prediction of correctly classifying as low-risk patients, but the FLIPI had the highest sensitivity to predict the risk of progression for critical patients.ConclusionsWe revealed the clinical characteristics and outcomes of FL patients in the real world in China, which may provide novel data on prognostic factors and primary treatment of FL, applicable to routine clinical practice. |
| first_indexed | 2024-04-12T19:05:04Z |
| format | Article |
| id | doaj.art-14d986aefcac43419ea87d00c8e3c574 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T19:05:04Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-14d986aefcac43419ea87d00c8e3c5742022-12-22T03:20:02ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.863021863021Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in ChinaFenghua Gao0Tingting Zhang1Xia Liu2Zhenjie Qu3Xianming Liu4Lanfang Li5Lihua Qiu6Zhengzi Qian7Shiyong Zhou8Wenchen Gong9Bin Meng10Xiubao Ren11Xianhuo Wang12Huilai Zhang13Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, ChinaDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, ChinaDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, ChinaDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, ChinaDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, ChinaDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, ChinaDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, ChinaDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, ChinaDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, ChinaDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Immunology/Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, ChinaDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, ChinaDepartment of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Sino-US Center for Lymphoma and Leukemia Research, Tianjin, ChinaBackgroundThe data about the clinical features and outcomes of Chinese patients with follicular lymphoma (FL) are limited. Here, we conducted a retrospective study to explore the initial treatment strategies and clinical outcomes of Chinese patients with FL in the real world.MethodThis study included FL patients who were newly diagnosed in Tianjin Medical University Cancer Institute and Hospital from March 2002 to August 2020.ResultsA total of 926 FL patients were enrolled. The median age was 54 years old, and the majority of the Chinese FL patients had advanced-stage disease and Eastern Cooperative Oncology Group(ECOG) <1 but less frequently infiltrated bone marrow. After a median of 38-month follow-up, the 5-year progressive-free survival (PFS) and overall survival (OS) of grade1–3a were 57.8% and 88.7%, respectively, which both are similar to those reported in previous Chinese and Western studies. The co-existence at diagnosis of FL and diffuse large B-cell lymphoma (DLBCL) components (FL/DLBCL) was associated with poor outcomes. The FL grades and proportion of DLBCL component in FL/DLBCL did not have an impact on PFS and OS. The most common regimen with great efficacy and risk–benefit was RCHOP-like followed by R maintenance regimen. The 5-year cumulative hazard of histological transformation (HT) was 4.7% (95% CI, 3.5–5.9); median time to transformation was 23.5 months (range, 2–146 months) after diagnosis. Three-year survival following transformation was 55% (95% CI, 40–70). Patients with stage III–IV, elevated β2 microglobulin (β2-MG), and B symptoms seemed to be more prone to progress within 24 months of frontline therapy (POD24). The FLIPI-2 showed the highest specificity to predict POD24, reflecting the prediction of correctly classifying as low-risk patients, but the FLIPI had the highest sensitivity to predict the risk of progression for critical patients.ConclusionsWe revealed the clinical characteristics and outcomes of FL patients in the real world in China, which may provide novel data on prognostic factors and primary treatment of FL, applicable to routine clinical practice.https://www.frontiersin.org/articles/10.3389/fonc.2022.863021/fullfollicular lymphomareal-worldChinesePOD24histological transformation |
| spellingShingle | Fenghua Gao Tingting Zhang Xia Liu Zhenjie Qu Xianming Liu Lanfang Li Lihua Qiu Zhengzi Qian Shiyong Zhou Wenchen Gong Bin Meng Xiubao Ren Xianhuo Wang Huilai Zhang Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China Frontiers in Oncology follicular lymphoma real-world Chinese POD24 histological transformation |
| title | Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China |
| title_full | Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China |
| title_fullStr | Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China |
| title_full_unstemmed | Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China |
| title_short | Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China |
| title_sort | clinical features and outcomes of patients with follicular lymphoma a real world study of 926 patients in china |
| topic | follicular lymphoma real-world Chinese POD24 histological transformation |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.863021/full |
| work_keys_str_mv | AT fenghuagao clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina AT tingtingzhang clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina AT xialiu clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina AT zhenjiequ clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina AT xianmingliu clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina AT lanfangli clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina AT lihuaqiu clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina AT zhengziqian clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina AT shiyongzhou clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina AT wenchengong clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina AT binmeng clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina AT xiubaoren clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina AT xianhuowang clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina AT huilaizhang clinicalfeaturesandoutcomesofpatientswithfollicularlymphomaarealworldstudyof926patientsinchina |